wsbdaily | Tue, 20 Dec 2022 03:11:24 EST Where you find Tomorrow’s Hot Stocks Yesterday!
NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
BioAtla, Inc.(BCAB)
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a... Read More
Summary & Charts
| Price | $ 7.55 | +1.19 (+18.71%) |
| Day's Range | $ 6.66 - 8.96 | |
| Previous Close | $ 6.36 | |
| Market Cap | $ 283.25M USD | |
| Short Interest % | N/A | |
| Float | N/A | |
| Outstanding | N/A |
| Exchange | NasdaqGM | |
| Industry | Biotechnology | |
| Sector | Healthcare | |
| Volume | 10.39M | |
| Avg. Volume (20 day) | 802.40K | |
| Rel. Volume (20 day) | 12.95 | |
| Rel. Volume (3 month) | 9.55 | |
| Rating | B | Neutral |
| DCF | N/A | Strong Buy |
| Debt/Equity | 21.36 % | Neutral |
| ROE | -37.86 % | Sell |
| ROA | -31.79 % | Sell |
| P/E | -3.84 % | Sell |
| P/B | 1.48 % | Buy |
| Date | Open | High | Low | Close | Change | Volume | R. Vol. (20d) | R. Vol. (3m) | Mentions |
|---|---|---|---|---|---|---|---|---|---|
| Nov 04, 2022 | $ 8.07 | $ 8.96 | $ 6.66 | $ 7.55 | +1.19 | 10,390,134 | 12.95 | 9.55 | |
| Nov 03, 2022 | $ 6.40 | $ 6.70 | $ 6.20 | $ 6.36 | -0.09 | 276,036 | 0.95 | 0.30 | |
| Nov 02, 2022 | $ 7.20 | $ 7.21 | $ 6.41 | $ 6.45 | -0.74 | 535,380 | 1.80 | 0.59 | |
| Nov 01, 2022 | $ 7.01 | $ 7.29 | $ 6.91 | $ 7.19 | +0.30 | 454,254 | 1.60 | 0.51 | |
| Oct 31, 2022 | $ 6.92 | $ 7.02 | $ 6.61 | $ 6.89 | -0.02 | 292,175 | 1.07 | 0.33 | |
| Oct 28, 2022 | $ 6.65 | $ 6.97 | $ 6.65 | $ 6.91 | +0.29 | 312,264 | 1.16 | 0.36 | |
| Oct 27, 2022 | $ 6.81 | $ 6.86 | $ 6.57 | $ 6.61 | -0.12 | 475,298 | 1.80 | 0.54 | |
| Oct 26, 2022 | $ 6.86 | $ 6.92 | $ 6.57 | $ 6.73 | -0.14 | 573,285 | 2.29 | 0.66 | |
| Oct 25, 2022 | $ 6.61 | $ 6.91 | $ 6.61 | $ 6.87 | +0.31 | 240,720 | 1.03 | 0.28 | |
| Oct 24, 2022 | $ 6.84 | $ 6.84 | $ 6.31 | $ 6.56 | -0.24 | 283,345 | 1.18 | 0.32 | |
| Oct 21, 2022 | $ 6.65 | $ 6.84 | $ 6.39 | $ 6.80 | +0.12 | 177,630 | 0.73 | 0.20 | |
| Oct 20, 2022 | $ 6.33 | $ 6.87 | $ 6.33 | $ 6.68 | +0.39 | 270,411 | 0.99 | 0.30 | |
| Oct 19, 2022 | $ 6.91 | $ 7.04 | $ 6.17 | $ 6.29 | -0.68 | 335,803 | 1.20 | 0.37 | |
| Oct 18, 2022 | $ 7.11 | $ 7.21 | $ 6.87 | $ 6.97 | +0.07 | 263,130 | 0.96 | 0.29 | |
| Oct 17, 2022 | $ 6.99 | $ 7.09 | $ 6.87 | $ 6.90 | +0.01 | 323,965 | 1.01 | 0.35 | |
| Oct 14, 2022 | $ 7.51 | $ 7.56 | $ 6.80 | $ 6.89 | -0.58 | 219,090 | 0.69 | 0.24 | |
| Oct 13, 2022 | $ 7.24 | $ 7.51 | $ 7.19 | $ 7.47 | -0.09 | 141,657 | 0.41 | 0.15 | |
| Oct 12, 2022 | $ 7.51 | $ 7.70 | $ 7.40 | $ 7.56 | +0.03 | 124,523 | 0.35 | 0.13 | |
| Oct 11, 2022 | $ 7.72 | $ 7.89 | $ 7.13 | $ 7.53 | -0.10 | 215,231 | 0.56 | 0.23 | |
| Oct 10, 2022 | $ 7.96 | $ 7.97 | $ 7.63 | $ 7.63 | -0.60 | 143,658 | 0.38 | 0.15 |
News
The latest news about BioAtla, Inc. (BCAB).
Zacks Investment Research | 2022-11-04 12:48:56
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire | 2022-10-27 08:00:00
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 3, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide business highlights.
Seeking Alpha | 2022-09-23 16:12:16
Shares of conditionally active biologics concern BioAtla, Inc. are beginning to rebound from a 97% plunge as encouraging data from two candidates has sparked the turnaround. BioAtla leverages its expertise of the tumor microenvironment to develop highly selective and reversible biologics, with applications across the entire antibody-based biologic spectrum.
Seeking Alpha | 2022-08-23 09:46:17
BioAlta shares have lost nearly three-quarters of their value over the past 3 years. Management has not done a good job of keeping lines of communication open and has a history of postponing clinical data timelines.
Earnings
| Date | Time | EPS Expected | EPS Reported | % | Revenue Expected | Revenue Reported | % |
|---|---|---|---|---|---|---|---|
| 2022-11-03 | BMO | -0.8 | -- | -- | 470K | -- | -- |
| 2022-08-09 | BMO | -0.69 | -0.77 | 11.59% | -- | -- | -- |
| 2022-05-05 | BMO | -0.69 | -0.65 | 5.8% | -- | -- | -- |
| 2022-03-01 | BMO | -0.63 | -0.62 | 1.59% | 370K | 250K | -32.44% |
| 2021-11-15 | BMO | -0.64 | -0.68 | 6.25% | 4.6M | -- | -- |
| 2021-08-13 | BMO | -0.56 | -0.90 | 60.71% | 243K | 250K | 2.84% |
| 2021-05-12 | BMO | -0.52 | -0.56 | 7.69% | -- | -- | -- |
| 2021-03-25 | BMO | -0.78 | -1.50 | 92.3% | -- | -- | -- |
Top Discussions
These are the top discussions over the last 24-hours that mention the BCAB stock ticker symbol.
Unusual Option Activity
Option contracts that are trading at a significantly higher volume relative to the contract's open interest. These might provide some insight into what "smart money" is doing with large volume orders.
| Type | Strike | Exp Date | DTE | Bid | Ask | Last | Volume | Open Interest | Vol/OI | IV |
|---|---|---|---|---|---|---|---|---|---|---|
| CALL | $ 15.00 | 01/19/23 | 75 | $ 0.65 | $ 1.15 | $ 2.30 | 132 | 39 | 3.38 | 1.76% |
Last Updated: Fri, 4 Nov 2022 22:57 EST
Failures to Deliver
Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.
Last Updated: Fri, 10 Dec 2021 12:00 EST
@wsbdaily
wsbdaily